New Migraine Treatment, Zecuity, Launched by Teva

Zecuity (sumatriptan iontophoretic transdermal system), which was initially approved by the FDA in January 2013, has been launched by Teva CNS for the treatment of migraine with or without aura in adults.

Zecuity is delivered via the skin through a low electrical current. It can be applied to either the upper arm or thigh, and delivers 6.5mg of sumatriptan over four hours.

Sumatriptan is a serotonin (5HT) 1B/1D receptor agonist. Its therapeutic effects are applied by binding to 5HT 1B/1D receptors – these are located on intracranial blood vessels and sensory nerves in the trigeminal system. This causes cranial vessel constriction and inhibition of pro-inflammatory neuropeptide as a result.

Zecuity is available as a single-use 6.5mg/4hrs transdermal system in 4-count cartons.

More information, including important safety information, can be obtained by calling (888) 483-8279 or by visiting Zecuity.com.

View References

Comments

View Comments (2)

Poll